Transcriptomics

Dataset Information

11

Gene expression profiles associated with pediatric relapsed AML


ABSTRACT: In high income countries 90% of the patients achieve complete remission after induction chemotherapy. However, 30-40% of these patients suffer from relapse. These patients face a dismal prognosis, as the majority (>60%) of relapsed patients die within 5 years. As a result, outcome for pediatric acute myeloid leukemia (AML) patients remains poor and has stabilized over the past 15 years. To prevent or better treat relapse of AML is the best option to improve outcome. Despite patient specific differences, most patients do respond to initial therapy. This suggests that at relapse, mechanisms are active that cause the altered response to chemotherapy. Detailed understanding of mechanisms that cause relapse remain largely elusive. To gain insight in the molecular pathways that characterize relapsed AML, we performed genome wide gene expression profiling on paired initial diagnosis and relapsed AML samples of 23 pediatric AML patients. We used pathway analysis to find which molecular pathways are involved in altered gene expression between diagnosis and relapse samples of individual AML patients. 23 paired diagnosis and relapse bone marrow or peripheral blood samples were collected and cryo-preserved. They were later thawed and processed for hybridization to Affymetrix U133 Plus 2.0 arrays.

ORGANISM(S): Homo sapiens  

SUBMITTER: Ursula Creutzig   Marry M van den Heuvel-Eibrink  C M Zwaan  Costa Bachas  Jacqeline Cloos  Dirk Reinhardt  Monique L Den Boer  Gert-Jan J Kaspers  Zinia J Kwidama  Eveline S de Bont  Gerrit J Schuurhuis 

PROVIDER: E-GEOD-52891 | ArrayExpress | 2015-05-07

SECONDARY ACCESSION(S): GSE52891PRJNA230404

REPOSITORIES: GEO, ArrayExpress

altmetric image

Publications


Development of relapse remains a problem for further improvements in the survival of pediatric AML patients. While virtually all patients show a good response to initial treatment, more patients respond poorly when treated at relapse. The cellular characteristics of leukemic blast cells that allow survival of initial treatment, relapse development and subsequent resistance to salvage treatment remain largely elusive. Therefore, we studied if leukemic blasts at relapse biologically resemble their  ...[more]

Similar Datasets

| GSE97135 | GEO
2011-09-23 | E-GEOD-28460 | ArrayExpress
2010-06-09 | E-GEOD-22056 | ArrayExpress
2013-02-12 | E-GEOD-41646 | ArrayExpress
2010-10-21 | E-GEOD-17855 | ArrayExpress
2011-09-22 | E-GEOD-28462 | ArrayExpress
2008-06-15 | E-GEOD-7210 | ArrayExpress
2010-03-10 | GSE18497 | GEO
| GSE46951 | GEO
2010-03-23 | E-GEOD-18497 | ArrayExpress